{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-26-000004","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.736499+00:00","generated_at":"2026-05-16T10:59:27.429390+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axogen reports preliminary Q4 revenue $59.9M (+21.3% YoY); full-year $225.2M (+20.2%); FDA BLA approval for Avance","bullets":["Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).","Gross margin expected above 74% for Q4 and FY 2025; includes ~$1.9M one-time costs related to Avance BLA approval, 67% non-cash.","Cash, equivalents, restricted cash, and investments ~$45.5M at Dec 31, 2025, up ~$6.0M from end of 2024.","FDA approved Biologics License Application for Avance (acellular nerve allograft) on Dec 3, 2025.","Growth driven by commercial strategy targeting Extremities and OMF-Head & Neck, and increased Resensation penetration."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-26-000004","json":"https://secwatch.observer/filing/0000805928-26-000004.json","markdown":"https://secwatch.observer/filing/0000805928-26-000004.md","text":"https://secwatch.observer/filing/0000805928-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000004/0000805928-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592826000004/axgn-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:27.429390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}